Third, evidence from the first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination Trialists Group) trial supports the use of aromatase inhibitors such as anastrozole for the adjuvant treatment of early breast cancer in postmenopausal women (Baum et al, 2002). The gene discussed is CYP19A1; the disease is breast cancer.